Sexual Dysfunction

A bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.

Sexual function/dysfunction topics discussed at the 2016 AUA included the findings of multiple studies on the effects of collagenase clostridium histolyticum (Xiaflex) treatment for Peyronie's disease, causes and treatments for ED, along with a study on patient satisfaction with implantable penile prostheses.

Other products discussed in this roundup include a plasma vaporization device, a laser fiber safety device, and more.

A men’s health expert explains implications of new data and how he will counsel patients.

"The fear of a hypothetical situation should not be used to place restrictions on the life of one of our transgender patients," writes Henry Rosevear, MD.

Other basic science research pearls include preliminary evidence from a porcine model suggesting botulinum toxin type A facilitates ureteral stone passage and the identification of two different microdeletions in the NELL1 gene on chromosome 11 in men with Peyronie's disease.

There is no excess risk of death, prostate cancer diagnosis, or cardiovascular events with long-term testosterone replacement therapy, Canadian researchers have found in a population-based matched cohort study.

In a study of intralesional collagenase clostridium histolyticum, mean curvature was reduced most dramatically after the first cycle, researchers reported.

A novel oral TRT agent, bladder control system, and localized prostate cancer agent are among other treatments in the pipeline discussed in this round-up.

One only needs to do a Google search for “testosterone clinic” to realize there’s an explosion of for-profit businesses branded as men’s health establishments, offering what sounds like the fountain of youth to men with “low T” and sexual dysfunction. Unless one of these practices is affiliated with an academic medical center or urology group, there’s a good chance urologists are not part of the picture.

Also look for coverage of products in the pipeline for bladder pain syndrome/interstitial cystitis, prostate cancer, and male infertility.

Peyronie’s disease (PD) is surgically treated by a minority of urologists, and urologists who subspecialize in andrology perform a disproportionate number of procedures to treat the condition. Those were among the findings of a case-log analysis that was presented at the 2015 AUA annual meeting in New Orleans and subsequently published in Urology (2016; 87:205-9).

Results from a recently published set of coordinated trials indicate that raising testosterone concentrations offers moderate benefits in sexual function and some benefit on mood and depressive symptoms.

Check out the latest new products. From Single-use ureteroscope addresses shortcomings of reusable scopes, to an App that helps IC, chronic prostatitis patients choose the right foods and much more.

The future of erectile dysfunction management following prostate cancer surgery will likely include novel options, among them cell-based therapies, North American experts in the field predict.

Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.

In this article, we review the etiology and pathophysiology of ED in this challenging patient population and provide an approach to treatment and risk reduction via lifestyle modification and pharmacologic intervention.

Learn more about these products as well as a powered exam table and an app that measures, monitors, and helps improve fertility in men.

Other pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.

The recently published AUA practice guideline on Peyronie’s disease provides current clinical principles on diagnosis and treatment of a highly prevalent and clinically significant condition, according to the co-chair of the multidisciplinary panel that developed the guideline.

Other products highlighted in this slideshow include a trial system for incontinence therapy, a compact catheter, a wearable digital technology solution for continence care assessment and management, and laser fiber and sheath system.

A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.

Shock wave therapy has now been subjected to multiple randomized, placebo-controlled, and additional open-label studies in clinics worldwide, demonstrating impressive efficacy and safety.

Experience with low-intensity extracorporeal shock wave therapy from multinational clinical trials demonstrates it is a safe, effective, and well-tolerated treatment for erectile dysfunction, including in men who do not respond to an oral phosphodiesterase type-5 inhibitor, reported Robert Feldman, MD, at the AUA annual meeting in New Orleans.

The association between testosterone replacement therapy (TRT) and thrombotic risk in elderly men remains controversial. While the FDA has mandated that all approved testosterone products include warnings about a possible increase in cardiovascular, stroke, and venous blood clot risk, at least one study presented at the AUA annual meeting in New Orleans found no link between TRT and cardiovascular events.